TrialRheumatology international2007

Anti-tumor necrosis factor-alpha antibody treatment reduces serum CXCL16 levels in patients with rheumatoid arthritis.

Yasunori Kageyama et al.PubMed ↗Publisher ↗

No numbers read from the abstract.